Factor XII (Hageman factor) deficiency
F12 deficiency; Hageman factor deficiency; Hageman trait; HAF deficiency
Factor XII deficiency is an inherited disorder that affects a protein (factor XII) involved in blood clotting.
When you bleed, a series of reactions take place in the body that helps blood clots form. This process is called the coagulation cascade. It involves special proteins called coagulation or clotting factors. You may have a higher chance of excess bleeding if one or more of these factors are missing or are not functioning as they should.
Factor XII is one such factor. A lack of this factor does not cause you to bleed abnormally. But, the blood takes longer than normal to clot in a test tube.
Factor XII deficiency is a rare inherited disorder.
There are usually no symptoms.
Exams and Tests
Factor XII deficiency is most often found when clotting tests are done for routine screening.
Tests may include:
Treatment is usually not needed.
These resources can provide more information on factor XII deficiency:
- National Hemophilia Foundation --
- National Organization for Rare Disorders --
- NIH Genetic and Rare Diseases Information Center --
The outcome is expected to be good without treatment.
There are usually no complications.
When to Contact a Medical Professional
The health care provider usually discovers this condition when running other lab tests.
This is an inherited disorder. There is no known way to prevent it.
Gailani D, Wheeler AP, Neff AT. Rare coagulation factor deficiencies. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 7th ed. Philadelphia, PA: Elsevier; 2018:chap 137.
Hall JE. Hemostasis and blood coagulation. In: Hall JE, ed. Guyton and Hall Textbook of Medical Physiology. 13th ed. Philadelphia, PA: Elsevier; 2016:chap 37.
Ragni MV. Hemorrhagic disorders: coagulation factor deficiencies. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap 174.
Last reviewed on: 1/29/2019
Reviewed by: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.